Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Window-of-opportunity phase II trial of Olaparib ± Durvalumab before primary debulking surgery in high-grade epithelial ovarian cancer
2024-511780-28-00Phase 2Authorised
- Sponsor
- AGO Research
- Start
- Mar 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib and durvalumab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by AGO Research. Primary endpoint: Feasibility of window-of-opportunity procedure. Planned start Mar 2024; status: authorised.
02
Drugs
olaparibdurvalumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-511780-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511780-28-00.